Benev soon to hire injectable reps for their toxin. Aaron Green is VP

Quote








anonymous said:
You only need to look at Merz to show this isn't true. Been around for 10+ years and have kept the exact same market share despite their buy one get one free sampling, ridiculously low price to large accounts, a large sales force, heavy marketing dollars (Gwen Paltrow, Aguilera, Jonas...). There will always be excitement for a new product from accounts and the cheap price will help, but practices are only going to put up with substandard product for so long then you'll be in the same boat as Merz handing out thousands of samples trying to appease price conscious doctors.

Agree with the comment that the label for this product sucks. It's got the lowest efficacy of any approved toxin by a large margin (45% really, you couldn't even get over 50 in a trial?) and the variability between the studies indicates its a dog sh-- manufacturing process. There's a reason Croma (their partner in Europe) had no issue giving up the U.S. rights. They have a dog on their hands and can't move the product in Europe. Product is also already available in Canada and hasn't done anything. Once they get outside South Korea they can't pull the same crap.

Easy to get down on this market, but the facts always show through. In Europe there's 100 cheap fillers and Restylane is still crushing. People want quality. Galderma's problems are with management and stupid quotas to feed what Fleming wants for his precious stock to grow.
Click to expand...
Merz’s issue is a different one. Family ownership, weak leadership, lack of ambition. It could do so much better and gain share. Croma, family ownership, no real leadership running the business. Galderma has toxic leadership but a growth ambition and aggressive targets. Allergan losing share due to AbbVie restrictions and competitive pressure. Revance is dead. Prollenium has no future. Evolus is one to watch. In such a landscape it’s relatively easy to survive and have an acceptable performance.
 




Having spent time wtih Merz Aesthetic, the quality of the product was 100% a problem. For cheap medspas they didn't care but if you converted a botox or dysport customer they'd complain about outcomes and you'd spend half your quarter dishing out samples to make sure they didn't completely drop you from the practice and you're basically begging to be a second or third option. Letybo looks even worse and I'm not going back to that kind of sale. I'm sure commission will be good at launch but in a few quarters the PE backers of Hugel will want more sales, quotas will skyrocket and customers will tune out.

Also, Benev only has a non-exclusive distribution license on the hugel toxin. Means Hugel can get another partner at any time. They're just renting the sales force and can drop them at any time. Not going to be stable which is what AG seems to love given his RVL debacle. Just ask the aesthetic reps who followed him there right into bankruptcy. Classic pump and dump scam artist.
 




























Top Bottom
Back
Quote